FDA-Approved Treatment Sequence and Dosing Strategies in GIST

Dr. Somaiah outlines the current FDA-approved sequence for advanced KIT-mutant GIST, emphasizing that community oncologists may encounter only handful of patients annually. First-line therapy uses imatinib 400mg daily, escalating to 400mg twice daily for KIT exon 9 mutations based on superior activity data.

Second-line standard remains sunitinib, originally approved at 50mg daily with 4-weeks-on/2-weeks-off scheduling based on placebo-controlled studies. However, practice has evolved toward continuous dosing at lower doses (37.5mg daily) for improved tolerability, with further reductions to 25mg or 12.5mg as needed to maintain patients on therapy.

Third-line regorafenib was approved at 160mg daily with 3-weeks-on/1-week-off scheduling, though many practitioners start at 120mg daily for elderly populations or those requiring dose modifications. Fourth-line ripretinib maintains its label dose of 150mg daily with optional escalation to twice daily for progression.

Dr. Somaiah emphasizes that response rates exceed 50% with imatinib but decline with each subsequent line. Second, third, and fourth-line approvals were based on progression-free survival advantages compared to placebo: sunitinib achieved over 6 months versus approximately 1 month, regorafenib 4.8 months versus less than 1 month, and ripretinib 6.3 months versus less than 1 month.

The panel discusses avapritinib as a fifth agent specifically for PDGFRA exon 18 mutations, particularly D842V, where tumor sensitivity allows starting at 200mg daily rather than the approved 300mg dose, significantly improving tolerability while maintaining efficacy.